nach oben

Erschienen in:

01.02.2005 | Review Article

Delayed emesis: moderately emetogenic chemotherapy

verfasst von: Fausto Roila, David Warr, Rebecca A. Clark-Snow, Maurizio Tonato, Richard J. Gralla, Lawrence H. Einhorn, Jorn Herrstedt

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2005

Einloggen, um Zugang zu erhalten

Abstract

Data on the incidence and efficacy of antiemetic prophylaxis against delayed emesis induced by moderately emetogenic chemotherapy are scanty. An overview of the literature has been done that showed the efficacy of dexamethasone in two of three randomized trials. Its optimal dose and duration of administration has not been defined. Only one of four randomized studies showed a statistically significant efficacy of 5-HT₃ antagonists. Finally, only weak evidence has been published on the efficacy of dopamine receptor antagonists.

Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the Perugia Consensus Conference. Ann Oncol 9:811–819CrossRefPubMed

ASHP Commission on Therapeutics (1999) ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatric patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm 56:729–764

Barrenetxea G, Schneider J, Centeno MM, et al (1996) Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens. Cancer Chemother Pharmacol 38:471–475CrossRefPubMed

De Angelis V, Roila F, Sabbatini R, et al (2003) Cancer chemotherapy-induced delayed emesis: antiemetic prescriptions in clinical practice. Proc ASCO 22:739

Eisenberg P, Figueroa-Vadillo J, Zamora R, et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist. Cancer 98:2473–2482CrossRefPubMed

ESMO Guidelines Task Force (2001). ESMO recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Ann Oncol 12:1059–1060CrossRefPubMed

Esseboom EU, Rojer RA, Borm JJ, et al (1995) Prophylaxis of delayed nausea and vomiting after cancer chemotherapy. Neth J Med 47:12–17CrossRefPubMed

Gralla RJ, Osoba D, Kris MG, et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994PubMed

Gralla R, Lichinitser M, Van der Vegt S, et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14:1570–1577CrossRefPubMed

10.

Grunberg SM, Hansen M, Deuson R, et al (2002) Incidence and impact of nausea and vomiting with modern antiemetics: perception versus reality. Proc. ASCO 21:250a

11.

Herrstedt J, Sigsgaard T, Boesgaard M, et al (1993) Ondansetron plus metopimazine compared with ondansetron alone in patients receiving moderately emetogenic chemotherapy. New Engl J Med 328:1076–1080CrossRefPubMed

12.

Inoue A, Yamada Y, Matsumura Y, et al (2003) Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 11:528–532CrossRefPubMed

13.

Italian Group for Antiemetic Research (1997) Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? Ann Oncol 8:561–567CrossRefPubMed

14.

Italian Group for Antiemetic Research (1998) Transferability to clinical practice of the results of controlled clinical trials: the case of antiemetic prophylactic treatment for cancer chemotherapy-induced nausea and vomiting. Ann Oncol 9:759–765CrossRefPubMed

15.

Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554–1559CrossRefPubMed

16.

Italian Group for Antiemetic Research (2004) Randomized, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol 22:725–729CrossRefPubMed

17.

Italian Group for Antiemetic Research (2004) Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions. Support Care Cancer 12(6):446–453CrossRefPubMed

18.

Kaizer L, Warr D, Hoskins P, et al (1994) Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 12:1050–1057PubMed

19.

Koo WH, Ang PT (1996) Role of maintenance oral dexamethasone in prophylaxis of delayed emesis caused by moderately emetogenic chemotherapy. Ann Oncol 7:71–74PubMed

20.

Pater JL, Lofters WS, Zee B, et al (1997) The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Ann Oncol 8:181–185CrossRefPubMed

21.

Stewart A, McQuade B, Cronje JDE, et al (1995) Ondansetron compared with granisetron in the prophylaxis of cyclophosphamide induced emesis in outpatients: a multicentre, double-blind, double dummy, randomised, parallel group study. Oncology 52:202–210PubMed

Titel: Delayed emesis: moderately emetogenic chemotherapy
verfasst von: Fausto Roila
David Warr
Rebecca A. Clark-Snow
Maurizio Tonato
Richard J. Gralla
Lawrence H. Einhorn
Jorn Herrstedt
Publikationsdatum: 01.02.2005
Verlag: Springer-Verlag
Erschienen in: Supportive Care in Cancer / Ausgabe 2/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-004-0700-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Delayed emesis: moderately emetogenic chemotherapy

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2005

Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines

Anticipatory nausea and vomiting

The 2004 Perugia Antiemetic Consensus Guideline process: methods, procedures, and participants

Forthcoming Meetings February 2005

Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity—an update

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie